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Pour en savoir plus
Kim IR, Cho J, Choi EK, Kwon IG (2012) Perception, Attitudes, Preparedness 
and Experience of Chemotherapy-Induced Alopecia among Breast Cancer 
Patients: a Qualitative Study 2012 Asian Pac J Cancer Prev 13: 1383-8
Roe H (2011) Chemotherapy-induced alopecia: advice and support for hair 
loss. Br J Nurs 20: S4-11
Grevelman EG, Breed WP (2005) Prevention of chemotherapy-induced hair 
loss by scalp cooling. Ann Oncol 3: 352-8
Th is article provides insight into the growth cycle of a hair follicle and the potential 
impact chemotherapy agents can have on this process, which often results in 
hair loss (alopecia). It explores the psychological consequences of chemotherapy-
induced alopecia for an individual as a result of the perceptions of others as well 
as an individual’s perception of his or her self-image. Despite the development of 
various forms of scalp cooling, chemotherapy-induced alopecia remains a major side 
eff ect for patients receiving chemotherapy; however, there have been improvements 
in wig provision and changing public opinion relating to baldness. Although 
chemotherapy-induced alopecia aff ects both males and females and all age groups, 
this article focuses on the potential impact for patients receiving chemotherapy as 
a form of treatment for breast cancer. As professionals we need to understand the 
social signifi cance of hair in relation to a person’s outward presentation and social 
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interactions, along with the possible psychological implications of a person losing 
his or her bodily hair, and not just the head hair. We must aim to minimize the 
distress alopecia can cause by: ensuring we provide patients with up-to-date verbal 
and written information to enable them to prepare for losing their hair; helping 
them to preserve their self-image and minimize the psychological consequences of 
hair loss while receiving chemotherapy; and preparing them for their hair re-growth 
following completion of chemotherapy.
van den Hurk CJ, Peerbooms M, van de Poll-Franse LV (2012) Scalp cooling 
for hair preservation and associated characteristics in 1411 chemotherapy 
patients – results of the Dutch Scalp Cooling Registry. Acta Oncol 51: 497-504
Chemotherapy-induced temporary hair loss is one of the most common and 
distressing side-eff ects of cancer therapy. Scalp cooling to reduce this hair loss is 
a controversial issue for many doctors and nurses. Th is may be due to inadequate 
knowledge.
Th is review from 53 publications and three personal communications focuses 
on the effi  cacy of the treatment, side-eff ects, possible disadvantages and the 
controversies in these areas.
Scalp cooling has become an increasingly eff ective method to prevent hair loss, 
especially when anthracyclines or taxanes are used. Unfortunately, many studies 
were small and badly designed and are therefore diffi  cult to compare. Th ere is 
a considerable variation in the success rates in the various studies. Th is remains 
unexplained, but the cooling time, the chemotherapy used and the temperature 
seem to be infl uential. Scalp cooling should not be used if chemotherapy is given 
with a curative intent in patients with generalised haematogenic metastases. Th e 
majority of patients tolerate cooling very well.
Scalp cooling is eff ective but not for all chemotherapy patients. Further 
psychological, clinical and biophysical research is needed to determine exact 
indications for cooling and to improve the eff ect, tolerance, side-eff ects and 
the cooling procedure. Multicentre trials should be carried out to gather this 
information.
Kluger N, Jacot W, Frouin E, Rigau V (2012) Permanent scalp alopecia 
related to breast cancer chemotherapy by sequential fl uorouracil/epirubicin/
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cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. 
Ann Oncol [Epub ahead of print]
Chemotherapy-induced alopecia is a frequently occurring side eff ect of cancer 
treatment with a high psychological impact which can be prevented by scalp 
cooling. With this multi-centre patient series we estimated the results of scalp 
cooling for currently used chemotherapies to provide patient information and 
we identifi ed characteristics associated with the results.
Th e Dutch Scalp Cooling Registry collected data on scalp-cooled patients in 
28 Dutch hospitals. Nurses and patients completed questionnaires on patients, 
chemotherapy and scalp cooling characteristics. Logistic regression analysis was 
used to examine associated characteristics of the scalp cooling result.
Overall, 50% of the 1411 scalp-cooled patients did not wear a head cover 
during their last chemotherapy session. Patients were satisfi ed with the results in 8% 
of cases after TAC chemotherapy and up to 95% after paclitaxel treatment. Besides 
type of chemotherapy, higher dose and shorter infusion time, older age, female 
gender and non-West-European type of hair signifi cantly increased the proportion 
head cover use. Hair length, quantity, chemical manipulation (dyeing, waving, 
colouring), wetting hair before scalp cooling, and treatment with chemotherapy 
ever before did not infl uence the degree of head covering among patients.
Scalp cooling results as recorded in this open patient registry were positive for 
most regimens, justifying it’s use by all eligible patients, except for those needing 
TAC. Lengthening infusion time may improve the results.
To analyze the clinical and histological features of permanent alopecia following 
a sequential fl uorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel 
regimen for adjuvant breast cancer treatment.
Women treated for breast cancer by a sequential adjuvant FEC and docetaxel 
regimen who developed permanent alopecia diagnosed between 2007 and 2011 
were identifi ed from the Department of Dermatology (Saint-Eloi Hospital, 
Montpellier, France) and the Department of Medical Oncology (CRLC Val 
d’Aurelle, Montpellier, France). Data were collected regarding demographics, type 
of cancer, delay of onset after chemotherapy, Dermatology Life Quality Index® 
(DLQI), clinical description of the lesions, scalp biopsies, laboratory explorations 
investigating steroid hormonal, iron, zinc and thyroid status, therapy and outcome.
Twenty white Caucasian females were included. Hair loss presented with a 
moderate or intense androgenetic-like pattern of scalp alopecia. Biopsy specimen 
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examinations were normal or displayed the androgenetic-like pattern. Laboratory 
explorations ruled out iron or zinc defi ciency and thyroid disorders and confi rmed 
hormonal menopause without hyperandrogenism. Th e overall mean DLQI score 
refl ected the distressing psychological consequences in the patients’ lives. No 
spontaneous regrowth of the scalp hair was noted. Treatment including vitamins, 
minoxidil, psoralen and ultraviolet A therapy and spironolactone proved to be 
ineff ective.
Permanent and severe alopecia is a newly reported complication of the FEC 
100-docetaxel breast cancer regimen.
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